- Page 1 and 2: 101 British Guideline on the Manage
- Page 3 and 4: British Thoracic Society Scottish I
- Page 5 and 6: Revised 2011 Revised 2011 Revised 2
- Page 7 and 8: 1 introduction 1.1 the need for A G
- Page 9 and 10: 1.3.1 PATIENT vERSION Patient versi
- Page 11 and 12: Table 1: Clinical features that inc
- Page 13 and 14: Case detection studies have used sy
- Page 15 and 16: 2.1.6 CHILDREN WITH AN INTERMEDIATE
- Page 17: 2.3 suMMAry focus the initial asses
- Page 21 and 22: 2.4.1 FURTHER INvESTIGATION OF PATI
- Page 23 and 24: Table 6: Differential diagnosis of
- Page 25 and 26: 2.5.1 TREATMENT TRIALS AND REvERSIB
- Page 27 and 28: A small prospective observational s
- Page 29 and 30: Table 8: Summary of tools that can
- Page 31 and 32: Measurement Methodology Asthma Cont
- Page 33 and 34: Measurement Methodology Eosinophil
- Page 35 and 36: 3.1.2 FOOD ALLERGEN AvOIDANCE Sensi
- Page 37 and 38: The limited data on antenatal or ea
- Page 39 and 40: 3.3.2 AIR POLLUTION Challenge studi
- Page 41 and 42: 3.5 CoMPleMentAry And AlternAtive M
- Page 43 and 44: Revised 2011 4 Pharmacological mana
- Page 45 and 46: Table 8b: Equivalent doses of inhal
- Page 47 and 48: 4.2.3 SAFETy OF INHALED STEROIDS Th
- Page 49 and 50: 4.3.2 ADD-ON THERAPy Options for ad
- Page 51 and 52: 4.4 steP 4: Poor Control on ModerAt
- Page 53 and 54: 4 PhArMAColoGiCAl MAnAGeMent Colchi
- Page 55 and 56: MOVE UP TO IMPROVE CONTROL AS NEEDE
- Page 57 and 58: 4.6 stePPinG doWn Stepping down the
- Page 59 and 60: 4.7.5 ASPIRIN-INTOLERANT ASTHMA The
- Page 61 and 62: 5.3 inhAled steroids for stABle Ast
- Page 63 and 64: Revised 2009 6 Management of acute
- Page 65 and 66: Patients with brittle or difficult
- Page 67 and 68: Table 11: Initial assessment - the
- Page 69 and 70:
In acute asthma without life threat
- Page 71 and 72:
6.3.8 ANTIBIOTICS 6.3.9 HELIOx When
- Page 73 and 74:
6.6.2 PATIENT EDUCATION Following d
- Page 75 and 76:
6.7.2 PULSE OxIMETRy 6.7.3 PEF Accu
- Page 77 and 78:
Frequent doses up to every 20-30 mi
- Page 79 and 80:
6.9.3 Iv MAGNESIUM SULPHATE Intrave
- Page 81 and 82:
New 2011 7 special situations 7.1 A
- Page 83 and 84:
Gender During adolescence there is
- Page 85 and 86:
Complementary and alternative medic
- Page 87 and 88:
Table 13: Recommendations for organ
- Page 89 and 90:
7.2 diffiCult AsthMA 7.2.1 DEFINING
- Page 91 and 92:
Revised 2009 Controlled studies usi
- Page 93 and 94:
Continuous fetal monitoring should
- Page 95 and 96:
C use steroid tablets as normal whe
- Page 97 and 98:
7.9.2 AT-RISK POPULATIONS Several h
- Page 99 and 100:
7.9.6 SPECIFIC BRONCHIAL PROvOCATIO
- Page 101 and 102:
Asthma clinics in primary care may
- Page 103 and 104:
A 8.3 Audit discharge from hospital
- Page 105 and 106:
9 Patient education and self manage
- Page 107 and 108:
9.2.1 COMPLIANCE WITH MONITORING AN
- Page 109 and 110:
Table 15. Summary of the key compon
- Page 111 and 112:
8. What role does patient preferenc
- Page 113 and 114:
Dr James Paton* Reader and Honorary
- Page 115 and 116:
INHALER DEvICES Dr John White (Chai
- Page 117 and 118:
11.4 disseMinAtion GrouP Mrs Sheila
- Page 119 and 120:
Abbreviations ABG arterial blood ga
- Page 121 and 122:
Annex 2 Management of acute severe
- Page 123 and 124:
Annex 4 Features of acute severe as
- Page 125 and 126:
Annex 6 Consider prednisolone 20 mg
- Page 127 and 128:
Annex 8 Management of acute asthma
- Page 129 and 130:
Annex 10 PEF (l/min) EU Scale 680 6
- Page 131 and 132:
Annex 11 (contd) Annexes 125
- Page 133 and 134:
56. Abu-Hasan M, Tannous B, Weinber
- Page 135 and 136:
156. Lodrup Carlsen KC, Carlsen KH,
- Page 137 and 138:
256. Malmstrom M, Ahlner J, Carlsso
- Page 139 and 140:
352. Brocklebank D, Ram F, Wright J
- Page 141 and 142:
456. McDowell KM, Chatburn RL, Myer
- Page 143 and 144:
562. McDonald JC, Keynes HL, Meredi
- Page 145 and 146:
668. Enright PL, McClelland RL, New
- Page 147 and 148:
767. Berger W. Budesonide inhalatio
- Page 149 and 150:
862. Pedroletti C, Lundahl J, Alvin
- Page 151:
ISBN 978 1 905813 28 5 British Thor